Fig. 5From: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosisPrognostic evaluation of MATH value in TP53 and FGFR3 mutations patients. a MATH values for TP53-mutant, FGFR3-mutant, and no mutation with TP53 and FGFR3, Kruskal-Wallis test (p < 0.05). b–g Kaplan–Meier survival analysis comparing patients in specific subgroups to all patients in the BLCA cohort from TCGABack to article page